Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Praxis Precision Medicines filings document regulatory disclosures for a CNS-focused biopharmaceutical issuer with common stock listed on the Nasdaq Global Select Market under PRAX. Its Form 8-K and 8-K/A reports cover material events, operating and financial results, clinical and regulatory updates, capital-structure disclosures, and leadership or board changes.
The company’s filing record includes disclosures related to ulixacaltamide HCl for essential tremor, elsunersen in SCN2A developmental and epileptic encephalopathy, and broader pipeline programs in movement disorders and epilepsy. Proxy materials address annual meeting matters, board composition, committee assignments, executive compensation, equity awards and other governance subjects.
Praxis Precision Medicines, Inc. reported insider equity transactions by Principal Accounting Officer Lauren Mastrocola. On January 8, 2026, she received 3,750 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. She was also granted a stock option for 7,500 shares of common stock at an exercise price of $294.38 per share, vesting over four years with 25% on January 8, 2027 and the remainder in 36 monthly installments. On January 10, 2026, 367 shares of common stock were withheld at $288.45 per share to satisfy tax withholding obligations related to vesting of previously reported restricted stock units, leaving her with 13,789.656 shares of common stock held directly.
Praxis Precision Medicines, Inc. (PRAX) Chief Operating Officer Megan Sniecinski reported new equity awards and a tax-related share withholding. On January 8, 2026, she was granted 9,625 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. Also on that date, she received a stock option for 7,700 shares at an exercise price of $294.38 per share, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 monthly installments.
On January 10, 2026, 1,087 shares of common stock were withheld at a price of $288.45 per share to cover tax obligations tied to previously reported restricted stock unit vesting. After these transactions, she directly held 29,415 shares of common stock and 7,700 stock options.
Praxis Precision Medicines’ General Counsel and Secretary, Alex Nemiroff, reported new equity awards and a tax-related share withholding. On January 8, 2026, he was granted 6,875 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of the January 8, 2026 vesting start date.
On the same date, he also received a stock option for 5,500 shares at an exercise price of $294.38 per share, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service. On January 10, 2026, 917 common shares were withheld at $288.45 per share to cover tax obligations from previously reported RSU vesting, leaving 26,700.667 common shares held directly and 5,500 options outstanding.
Praxis Precision Medicines’ Chief Financial Officer Timothy Edwin Kelly reported new equity awards and a tax-related share withholding. On January 8, 2026, he received 8,800 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. That same day he was granted a stock option for 7,040 shares at an exercise price of $294.38 per share, vesting 25% on January 8, 2027 and the remaining 75% in 36 monthly installments, subject to continued service. On January 10, 2026, 1,335 shares of common stock were withheld at $288.45 per share to cover tax obligations tied to earlier RSU vesting. After these transactions, he directly beneficially owned 31,989 common shares and 7,040 stock options.
Praxis Precision Medicines, Inc. Chief Executive Officer and director Marcio Souza reported new equity awards and related share activity. On January 8, 2026, he was awarded 27,640 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on January 8, 2026. That same day, he received a stock option for 22,110 shares of common stock at an exercise price of $294.38, vesting 25% on January 8, 2027 and the remaining 75% in 36 equal monthly installments thereafter, subject to continued service. On January 10, 2026, 4,252 shares of common stock were withheld at $288.45 per share to satisfy tax withholding obligations on previously reported RSU vesting. After these transactions, he directly beneficially owned 76,890 shares of common stock, 22,110 stock options, and indirectly held 2,600 shares through his spouse.
Praxis Precision Medicines director reports no share ownership
Praxis Precision Medicines, Inc. director Arbuckle Stuart A filed an initial insider ownership report. The filing states that no securities of Praxis Precision Medicines are beneficially owned by the reporting person as of the event date of January 8, 2026. The form is filed by a single reporting person and is signed by an attorney-in-fact, supported by a power of attorney.
Praxis Precision Medicines, Inc. filed an initial ownership report for director Jeffrey B. Kindler as of 01/08/2026. The filing is a Form 3, which is used when someone first becomes an insider such as a director or officer.
In the remarks, the report states that no securities are beneficially owned, meaning the reporting person did not report holding any Praxis Precision Medicines stock or derivative securities at the time of this filing. The form is signed by an attorney-in-fact under a power of attorney dated 01/12/2026.
Praxis Precision Medicines, Inc. reported an insider equity transaction by its Principal Accounting Officer, Lauren Mastrocola. On January 7, 2026, 35 shares of Praxis common stock were withheld by the company at a price of $292.63 per share to cover tax obligations tied to the vesting of previously reported restricted stock units. After this tax withholding, Mastrocola beneficially owns 10,406.656 shares of Praxis common stock directly.
Praxis Precision Medicines General Counsel and Secretary Alex Nemiroff reported an automatic share withholding related to equity compensation. On January 7, 2026, 89 shares of common stock were withheld by the company at a price of $292.63 per share to cover tax obligations tied to the vesting of previously reported restricted stock units. After this tax withholding event, Nemiroff beneficially owned 20,742.667 shares of Praxis Precision Medicines common stock, held directly.
Praxis Precision Medicines, Inc. reported an insider equity transaction by its Chief Financial Officer, Kelly Timothy Edwin. On 01/07/2026, 139 shares of common stock were withheld by the company at a price of $292.63 per share to satisfy tax withholding obligations related to the vesting of previously reported restricted stock units. Following this tax-related withholding, the officer directly beneficially owned 24,524 shares of Praxis common stock.